title: Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients.
authors.forename: Esther
authors.initials: E
authors.lastname: Gonzalez
authors.forename: Jorge
authors.initials: J
authors.lastname: Rojas-Rivera
authors.forename: Natalia
authors.initials: N
authors.lastname: Polanco
authors.forename: Enrique
authors.initials: E
authors.lastname: Morales
authors.forename: José María
authors.initials: JM
authors.lastname: Morales
authors.forename: Jesus
authors.initials: J
authors.lastname: Egido
authors.forename: Andres
authors.initials: A
authors.lastname: Amado
authors.forename: Manuel
authors.initials: M
authors.lastname: Praga
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D004872:Ergocalciferols / Q000008:administration & dosage*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D016030:Kidney Transplantation / Q000009:adverse effects*; D016015:Logistic Models; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D010281:Parathyroid Hormone / Q000097:blood; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004872:Ergocalciferols; C470125:PTH protein, human; D010281:Parathyroid Hormone; C084656:paricalcitol